"One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes

Clin Infect Dis. 2021 Oct 20;73(8):1532-1536. doi: 10.1093/cid/ciab535.

Abstract

Mycobacterium abscessus subsp. abscessus is one of the most difficult pathogens to treat and its incidence in disease is increasing. Dual β-lactam combinations act synergistically in vitro but are not widely employed in practice. A recent study shows that a combination of imipenem and ceftaroline significantly lowers the minimum inhibitory concentration of clinical isolates, despite both drugs targeting the same peptidoglycan synthesis enzymes. The underlying mechanism of this effect provides a basis for further investigations of dual β-lactam combinations in the treatment of M. abscessus subsp. abscessus, eventually leading to a clinical trial. Furthermore, dual β-lactam strategies may be explored for other difficult mycobacterial infections.

Keywords: Mycobacterium abscessus; L,D-transpeptidase; ceftaroline; dual beta-lactam; imipenem.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Drug Synergism
  • Humans
  • Lactams
  • Microbial Sensitivity Tests
  • Mycobacterium Infections, Nontuberculous* / drug therapy
  • Mycobacterium abscessus*
  • Peptidoglycan

Substances

  • Anti-Bacterial Agents
  • Lactams
  • Peptidoglycan